A Study of Clofarabine for Older Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) (CLASSIC II)

Completed · Phase 2

Conditions studied: Acute Myelogenous Leukemia, Acute Myeloid Leukemia

In brief

Clolar (clofarabine injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute lymphoblastic leukemia (ALL) who have had at least 2 prior treatment regimens. This study will evaluate the efficacy of clofarabine in elderly patients with acute myelogenous leukemia (AML) who are unlikely to benefit from treatment with intensive chemotherapy regimens (cytarabine and anthracycline based regimens) used in younger patients with AML.

Key facts

Study ID

NCT00373529

Run by

Genzyme, a Sanofi Company

People needed

116

Starts

2006-10-01

Expected to finish

2010-05-01

Last updated by the study team

2014-04-14

Who can join

Age: 60 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of AML (de novo, secondary or with an antecedent hematologic disorder [AHD])
• Age ≥ 60 years
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2
• Presence of at least one adverse prognostic factor: Age ≥ 70 years; or AHD; or ECOG performance status of 2; or Intermediate or unfavorable (i.e., adverse) karyotype defined as any cytogenetic profile except the presence of any of the following:
• t(8;21)(q22;q22)
• inv(16)(p13;q22 or t(16;16)(p13;q22)
• t(15;17)(q22;q12) and variants.
• Adequate renal and hepatic function: Total bilirubin ≤ 1.5 x upper limit of normal (ULN); Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN; and Serum creatinine ≤ 1.0 mg/dL; if serum creatinine > 1.0 mg/dL, then the estimated glomerular filtration rate (GFR) must be > 60 mL/min/1.73 m\^2 as calculated by the Modification of Diet in Renal Disease (MDRD) equation
• Adequate cardiac function: left ventricular ejection fraction (LVEF) ≥ 40% or left ventricular fractional shortening ≥ 22%

You may not qualify if…

• Diagnosis of acute promyelocytic leukemia
• Prior treatment with clofarabine
• Prior treatment for AML or an antecedent hematologic disorder
• Prior hematopoietic stem cell transplant (HSCT)
• Prior radiation therapy to the pelvis
• Investigational agent received within 30 days prior to the first dose of study drug
• Ongoing uncontrolled systemic infection
• Diagnosis of another malignancy, unless the patient has been disease-free for at least 5 years following the completion of curative intent therapy with the following exceptions: Patients with treated non-melanoma skin cancer, in-situ carcinoma or cervical intraepithelial neoplasia regardless of disease-free duration are eligible for this study if definitive treatment for the condition has been completed; Patients with organ-confined prostate cancer with no evidence of recurrent or progressive disease based on PSA value are eligible for this study if hormonal therapy has been initiated or a radical prostatectomy has been performed
• Clinical evidence of central nervous system (CNS) involvement
• Severe concurrent medical condition or psychiatric disorder that would preclude study participation
• Positive human immunodeficiency virus (HIV) test

Where it is running

• Mayo Clinical Hospital — Phoenix, Arizona, United States
• Arizona Cancer Center — Tucson, Arizona, United States
• USC/Norris Comprehensive Cancer Center and Hospital — Los Angeles, California, United States
• Scripps Cancer Center — San Diego, California, United States
• Rocky Mountain Cancer Centers — Denver, Colorado, United States
• Cancer Center of Central Connecticut — Southington, Connecticut, United States
• Emory University School of Medicine — Atlanta, Georgia, United States
• Medical College of Georgia — Augusta, Georgia, United States
• Rush University Medical Center — Chicago, Illinois, United States
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States
• Mount Sinai School of Medicine — New York, New York, United States
• Oregon Health and Science University — Portland, Oregon, United States
• Penn State Hershey Medical Center — Hershey, Pennsylvania, United States
• Vanderbilt University Medical Center — Nashville, Tennessee, United States
• University of MD Anderson Cancer Center — Houston, Texas, United States
• Cancer Care Centers of South Texas — San Antonio, Texas, United States
• University of Utah - Huntsman Cancer Institute — Salt Lake City, Utah, United States
• Seattle Cancer Care Alliance — Seattle, Washington, United States
• West Virginia University - HSC — Morgantown, West Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.